- Baked In
- Posts
- ⚕️ Avicanna’s IP: Fast-Onset, Precision-Dosed, Ready to License Worldwide
⚕️ Avicanna’s IP: Fast-Onset, Precision-Dosed, Ready to License Worldwide

Good morning, loyal readers —
Avicanna just checked a major box on its operational roadmap, flipping to positive adjusted EBITDA right on the schedule management laid out earlier this year. The improvement came from sharper cost control, expanding gross margins, and a clear shift toward higher-margin proprietary products — including the rapid-onset QUIX line that is already gaining traction. While the Canadian medical channel remains structurally tight, the company is building the clinical data, hospital relationships, and formulation IP that could matter both at home and in export markets. Execution is real; the next question is whether that foundation can start generating growth.
Scroll down for our full analysis…

Own Your Edge. TDR subscribers that are new customers get 15% off: https://frepouch.com/discount/DALES
💸 The Tape
Avicanna reported positive adjusted EBITDA of C$0.22 million for the third quarter, delivering on a target management set earlier in the year and marking a C$1.01 million improvement from the C$0.79 million loss a year ago. CEO Aras Azadian’s framing, “as projected,” is the point. The company said it would get here and it did.
What actually happened
Revenue was C$5.73 million, down 10% year over year but up 2% sequentially, the first quarter-on-quarter increase since the April 2026 Veterans Affairs Canada reimbursement changes cut into MyMedi.ca’s largest patient cohort. Nine-month revenue is C$18.05 million, down 4%. So the top line is still shrinking on an annual basis; it has just stopped shrinking faster.
The EBITDA turn came from the cost side. Operating expenses fell 30% to C$3.19 million, gross margin expanded to 51% from 49%, and the operating loss narrowed 80% to C$0.27 million. Working capital swung from a C$1.28 million deficit at year-end to a C$0.11 million surplus. These are real improvements in a business that was burning cash on a C$6 million revenue base. They are also the kind of improvements that come from cutting, not growing, and there’s a limit to how many quarters that math works.
The mix shift is the more durable development. Proprietary products reached 31% of MyMedi.ca sales, up from 19% a year earlier, with 176,694 proprietary units sold through nine months, a 16% increase. The commercial SKU count climbed 21% in a quarter to 68, and the QUIX nano-emulsion line launched with 10 rapid-onset capsule and soft-chew SKUs. Every point of proprietary share is a point of margin that doesn’t go to a third-party brand. That’s the lever that gets gross margin from 51% toward 60%, and it’s the part of the strategy that’s demonstrably working.
The Canadian medical problem
Here is the structural issue Avicanna can’t cost-cut its way around. Canada’s medical cannabis channel has been in decline since adult-use legalization in 2018. Patients who once needed a medical document to access product now walk into a retail store. The registry has fallen from a peak near 370,000 to a fraction of that, and the remaining base skews toward veterans, chronic pain patients and others whose insurance covers the cost. Veterans Affairs Canada is the single largest third-party payer in the system, and when it changed reimbursement rules in April, every medical platform in the country felt it. Avicanna’s MyMedi.ca is a direct-to-patient medical dispensary. It’s exposed by design.
The company’s response is the right one on paper. The Integrated Healthcare Program pushes MyMedi.ca into hospitals, specialty clinics and healthcare networks, trying to position medical cannabis as a provider-guided therapy rather than a self-selected one. The clinical pipeline, a real-world evidence study, a University of Calgary THC dose-finding trial, a University Health Network osteoarthritis pilot, is built to generate the data that physicians and payers ask for before they’ll prescribe or reimburse. If medical cannabis has a future in Canada as a distinct channel, it looks like this: evidence-based, clinician-integrated, insurance-reimbursed, with pharmaceutical-grade formulations that retail doesn’t offer.
The problem is timing. Clinical studies take years. Hospital procurement cycles take years. Insurance formulary decisions take years. Avicanna is running a 12-month debenture against a strategy with a 36-month payoff horizon, in a channel that’s shrinking in the meantime. The go-forward for Canadian medical isn’t that it disappears; it’s that it consolidates to a few platforms that can prove clinical and economic value to institutional payers. Avicanna is building toward being one of them. It hasn’t yet shown it can fund the wait.
International as the hedge
The other leg is export. Aureus Santa Marta, the Colombian cultivation subsidiary, supplies CBD, THC and CBG active ingredients to international partners, and RHO Phyto is “expanding into new international markets,”. Colombian low-cost cultivation feeding EU-GMP markets is the thesis that’s working for Village Farms and Cronos out of Canada. Avicanna has the geography but not, so far, the disclosed volume. The U.S. angle Azadian has been pointing at, that rescheduling creates demand for pharmaceutical cannabinoid formulations and the IP behind them, is plausible and entirely speculative at this stage.
Is it working?
Partly. The operational turnaround is real: 30% lower opex, higher margins, proprietary products taking share, positive adjusted EBITDA on schedule. That’s execution, and it deserves credit. What isn’t yet working is revenue, which is still down year over year, and cash generation, which is evidently insufficient given the terms of the October raise. The company has stabilized the patient. It hasn’t restored growth.
The realistic read is that Avicanna has bought itself a year to prove that the Integrated Healthcare Program and the QUIX line can turn a shrinking medical channel into a growing one, while the Colombian export business and the clinical pipeline mature in the background. If proprietary share keeps climbing and the hospital program lands even a few institutional accounts, the story changes. If revenue is still down next November and the debentures need rolling, the 2026 EBITDA milestone will look like the end of a cost program rather than the start of a business.
📈 Dog Walkers
$HELP ( ▲ 0.11% ) Reports Positive Phase 3
Helus Pharma reported topline results from APPROACH, the first of two pivotal trials of HLP003, a deuterated psilocin, as an add-on treatment for major depressive disorder. The numbers are not subtle. At six weeks, patients on HLP003 improved 19.5 points on the MADRS scale versus 11.9 on placebo, a 7.6-point separation with p<0.0001 and an effect size of 0.65. For reference, most approved antidepressants clear placebo by two to three points. Compass’s psilocybin program, now under FDA review, separated by roughly 3.6 to 5 points in its Phase 3s.
The response curve matters as much as the magnitude. Half of HLP003 patients responded by Day 2, against 24% on placebo, and 39% were in remission within 48 hours of dosing. At week 12, more than a month and a half after a single administration, 45% remained responders and 40% remained in remission, roughly double the placebo arm on both. That’s the durability signal the field has been trying to prove since the first Johns Hopkins papers.
Dr. Roger McIntyre of the University of Toronto called it “a new benchmark for what may be achievable with adjunctive treatment.” Allowing for the fact that he’s quoted in the company’s release, the data support the language.
The gaps are the usual ones for a topline. Three treatment-related serious adverse events occurred in the active arm with no detail on what they were, and in a 112-patient arm that’s a rate worth watching. Functional unblinding, the chronic problem in psychedelic trials, isn’t addressed. No NDA timeline, no cash figure, and the second pivotal, EMBRACE, doesn’t read out until Q4 2027, which puts a filing into 2028 at the earliest.
Still, with Compass’s NDA under review and HLP003 holding Breakthrough designation, the psychedelic depression category now has two late-stage programs with convincing data. One trial doesn’t make a drug. This one makes the sector much harder to dismiss.
$ROMJ.TSX ( 0.0% ) Reports Q3
Rubicon Organics reported Q3 net revenue of C$18.3 million, up 17% year over year, and year-to-date revenue of C$50.4 million, also up 17%. In a Canadian market where most producers are flat, that’s growth worth noting. The company holds the #1 premium licensed producer position on Hifyre data with a 6.6% share, leads premium flower at 9.0%, and its Wildflower line is the #2 topical brand with a 31.4% share and the top-selling topical SKU in the country. The premium niche Rubicon carved out in 2020 is still the only segment of Canadian cannabis holding price, and Rubicon still owns it.
The profitability story is slower. Adjusted EBITDA was C$1.4 million, down 17% from a year ago but up 27% sequentially. That compression is the cost of Cascadia, the 47,500-square-foot indoor facility in Hope that began generating revenue late in Q2 and contributed about C$2.3 million in Q3. The ramp is running roughly six months behind plan, which means the fixed costs showed up before the yields did. Pacifica, the Delta greenhouse, is performing better, with year-to-date yields up 16% on the new lighting and capacity expected to reach 15,500 kilograms in 2027.
International sales were 11.7% of revenue, with four export contracts signed. That’s the margin lever: EU-GMP-adjacent premium flower sells for multiples of the Canadian rec price, and Cascadia’s new CUMCS and IMC-G.A.P. certifications open Israel and Australia. Arbora, the new genetics facility, received its micro-cultivation license after quarter-end.
The gaps: no gross margin, net income, cash or debt in the release, and no numeric guidance. Margaret Brodie frames 2026 as “building the platform for the next growth stage,” with in-house hydrocarbon extraction coming online in H2 2027 and 20,000 kilograms of combined capacity by mid-year.
Rubicon is doing what it said it would. The 2027 question is whether the margins catch up to the volume.
🗞️ The News
📺 Trade To Black
Is a State Cannabis Wave Coming? | TTB Weekly Recap
State reform momentum is building post-midterms: Texas Lt. Gov.-elect Vikki Goodwin says the options range from expanding TCUP to full legalization, with GOP Rep. Wes Virdell signaling common ground ahead of the January 12 session. Wisconsin’s Gov.-elect Crowley ties legalization to offsetting Medicaid cuts, and North Carolina’s incoming Speaker says decriminalization is on “everybody’s minds.”
Earnings keep improving: MariMed posts record revenue of $44.2M, up 8.5%; Ascend hits $130M with $31.1M adjusted EBITDA and 61 stores; Village Farms logs record cannabis revenue of $55M with exports up 75% and about $80M in cash.
Deal flow continues: Vireo closes FLUENT for roughly 74 Florida dispensaries, Chicago Atlantic covers its $0.47 dividend with $0.49 in distributable earnings, and Compass Pathways completes its FDA filing for COMP360.
Consolidation watch: with Organigram’s BAT-backed bid for Aurora on the table, the question is who moves next.

